glp-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Frontiers | GLP-1 Receptor Agonists:

Supplements cannot legally claim to diagnose, treat, cure, or prevent disease

Thats because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes

Thirdly , theres also a patent application (IN202047010224) (pdf) pending by Novo Nordisk, filed in 2020 with priority date of 24/08/2017, for a specific formulation of semaglutide (the active ingredient in its commercial blockbuster drug, Ozempic) described as Semaglutide liquid formulations (no more than 0.01% (w/w) phenol. Adding to the complexity is a recent revocation petition filed by DRL in May 2025 (as reported by the media here)

Methods Construction of an Exendin-4-based membrane-tethered combinatorial peptide library The expression of transmembrane-tethered Exendin-4 was under control of EF1a in the lentiviral vector